2-TUR QANDLI DIABET VA KOGNITIV BUZILISHLAR: ZAMONAVIY MA’LUMOTLAR SHARHI
##article.subject##:
2-tur qandli diabet, kognitiv buzilishlar, demensiya, giperglikemiya, neyroyallig‘lanish, gipoglikemik terapiya##article.abstract##
2-tur qandli diabet (QD2) kognitiv buzilishlar va demensiya rivojlanishining muhim xavf omili hisoblanadi. Surunkali giperglikemiya va insulinrezistentlik fonida shakllanadigan metabolik, tomir va yallig‘lanish mexanizmlari markaziy asab tizimida strukturaviy va funksional o‘zgarishlarga olib keladi. Ushbu tadqiqotda QD2 bilan og‘rigan bemorlarda kognitiv holat kompleks baholandi hamda klinik-metabolik ko‘rsatkichlar va olib borilayotgan qandni pasaytiruvchi terapiyaning ta’siri tahlil qilindi. Kasallik davomiyligi, HbA1c darajasi va tomir asoratlarining mavjudligi kognitiv pasayish darajasi bilan bog‘liqligi aniqlandi. Olingan natijalar QD2 bilan og‘rigan bemorlarda kognitiv buzilishlarni erta skrining qilish va potensial neyroprotektiv ta’sirga ega bo‘lgan terapiyani asosli tanlash zarurligini tasdiqlaydi.
Библиографические ссылки
Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus. Nat Rev Endocrinol. 2018.
Cheng G et al. Type 2 diabetes and risk of dementia: a meta-analysis. Neurology. 2012.
Gudala K et al. Diabetes mellitus and risk of dementia: systematic review. J Diabetes Investig. 2013.
Brownlee M. The pathobiology of diabetic complications. Nature. 2001.
Butterfield DA et al. Oxidative stress in Alzheimer’s disease brain. Free Radic Biol Med. 2013.
De Felice FG, Ferreira ST. Insulin resistance and Alzheimer’s disease. Neurobiol Aging. 2014.
Talbot K et al. Demonstrated brain insulin resistance in Alzheimer’s disease. J Clin Invest. 2012.
Arnold SE et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease. Nat Rev Neurol. 2018.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011.
Moran C et al. Type 2 diabetes and brain structural changes. Diabetes Care. 2013.
Palta P et al. Type 2 diabetes and cognitive decline. Diabetes Care. 2014.
Cukierman-Yaffe T et al. Diabetes and cognitive decline in older adults. Lancet Neurol. 2009.
Feil DG et al. Cognitive impairment and medication adherence in diabetes. J Gen Intern Med. 2012.
Gejl M et al. GLP-1 analog and brain glucose metabolism. Front Aging Neurosci. 2016.
Salcedo I et al. Neuroprotective effects of GLP-1 receptor agonists. Mol Neurobiol. 2012.
Zinman B et al. Empagliflozin cardiovascular outcomes. N Engl J Med. 2015.
Campbell JM et al. Metformin use and dementia risk. J Am Geriatr Soc. 2018.
Kosaraju J et al. DPP-4 inhibitors and neuroprotection. Brain Res Bull. 2013.
